ALK and non-small cell lung carcinoma: IMpower 131, a multicenter phase 3 trial, included patients with metastatic squamous NSCLC without EGFR mutations or ALK rearrangements regardless of PD-L1 status, divided in 1:1:1 arm to receive atezolizumab + carboplatin + paclitaxel (A + CP), atezolizumab + carboplatin + nab-paclitaxel (A + CnP), or carboplatin + nab-paclitaxel (CnP).